OGN * Stock Overview
Develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$343.00 |
| 52 Week High | US$426.40 |
| 52 Week Low | US$195.00 |
| Beta | 0.80 |
| 11 Month Change | 0% |
| 3 Month Change | -17.35% |
| 1 Year Change | 80.53% |
| 33 Year Change | -46.82% |
| 5 Year Change | n/a |
| Change since IPO | -51.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| OGN * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | -0.3% |
| 1Y | 80.5% | -19.3% | -4.0% |
Return vs Industry: OGN * exceeded the MX Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: OGN * exceeded the MX Market which returned -4% over the past year.
Price Volatility
| OGN * volatility | |
|---|---|
| OGN * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.7% |
Stable Share Price: OGN *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine OGN *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10,000 | Kevin Ali | www.organon.com |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
Organon & Co. Fundamentals Summary
| OGN * fundamental statistics | |
|---|---|
| Market cap | Mex$80.60b |
| Earnings (TTM) | Mex$26.65b |
| Revenue (TTM) | Mex$131.26b |
3.0x
P/E Ratio0.6x
P/S RatioIs OGN * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OGN * income statement (TTM) | |
|---|---|
| Revenue | US$6.41b |
| Cost of Revenue | US$2.68b |
| Gross Profit | US$3.73b |
| Other Expenses | US$2.43b |
| Earnings | US$1.30b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.05 |
| Gross Margin | 58.26% |
| Net Profit Margin | 20.30% |
| Debt/Equity Ratio | 1,774.6% |
How did OGN * perform over the long term?
See historical performance and comparisonDividends
7.3%
Current Dividend Yield22%
Payout RatioDoes OGN * pay a reliable dividends?
See OGN * dividend history and benchmarks| Organon dividend dates | |
|---|---|
| Ex Dividend Date | Nov 12 2024 |
| Dividend Pay Date | Dec 12 2024 |
| Days until Ex dividend | 12 days |
| Days until Dividend pay date | 18 days |
Does OGN * pay a reliable dividends?
See OGN * dividend history and benchmarks